Education
About Us
Working with TipRanks
Follow Us
Boston Scientific (GB:0HOY)
:0HOY
0HOY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$77.67 - $109.09
Previous CloseN/A
Volume17.35K
Average Volume (3M)4.07K
Market Cap
$152.87B
Enterprise Value$172.04B
Total Cash (Recent Filing)$725.00M
Total Debt (Recent Filing)$11.71B
Price to Earnings (P/E)61.3
Beta0.74
Next Earnings
Oct 22, 2025EPS Estimate
0.72Last Dividend Ex-Date
Mar 15, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)0.75
Shares Outstanding1,481,751,600
10 Day Avg. Volume2,665
30 Day Avg. Volume4,073
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue9.80
Enterprise Value/Gross Profit15.85
Enterprise Value/Ebitda41.37
Forecast
1Y Price Target
$125.09Price Target Upside21.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
Bulls Say, Bears Say
Bulls Say
EarningsBoston Scientific reported Q2 revenue and EPS ahead of expectations due to strong performance in PFA and Watchman products.
Growth OutlookBSX raised its 2025 organic growth guidance to 14-15%, which is higher than previous estimates.
Product InnovationThe label expansion for Watchman to include the option to use Intracardiac Echocardiography (ICE) can materially speed up the procedure as it removes the need for general anesthesia.
Bears Say
Product AdvisoryBoston Scientific issued a physician advisory letter highlighting calcification risk in older-generation ePTFE-coated ENDOTAK RELIANCE defibrillation leads.
Product DiscontinuationManagement anticipates an impact on Interventional Cardiology due to the neo2 discontinuation.
Sales ImpactThe adjusted income statement had a $100m impact in Q2 with the majority of this being inventory charges and the rest being sales returns.
Boston Scientific News
0HOY FAQ
What was Boston Scientific’s price range in the past 12 months?
Boston Scientific lowest share price was $77.67 and its highest was $109.09 in the past 12 months.
What is Boston Scientific’s market cap?
Boston Scientific’s market cap is $152.87B.
When is Boston Scientific’s upcoming earnings report date?
Boston Scientific’s upcoming earnings report date is Oct 22, 2025 which is in 66 days.
How were Boston Scientific’s earnings last quarter?
Boston Scientific released its earnings results on Jul 23, 2025. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.725 by $0.025.
Is Boston Scientific overvalued?
According to Wall Street analysts Boston Scientific’s price is currently Undervalued.
Does Boston Scientific pay dividends?
Boston Scientific pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Boston Scientific dividends here
What is Boston Scientific’s EPS estimate?
Boston Scientific’s EPS estimate is 0.72.
How many shares outstanding does Boston Scientific have?
Boston Scientific has 1,481,751,600 shares outstanding.
What happened to Boston Scientific’s price movement after its last earnings report?
Boston Scientific reported an EPS of $0.75 in its last earnings report, beating expectations of $0.725. Following the earnings report the stock price went up 3.481%.
Which hedge fund is a major shareholder of Boston Scientific?
Currently, no hedge funds are holding shares in GB:0HOY
Boston Scientific Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$125.09 (21.27% Upside)
$125.09 (21.27% Upside)
Blogger Sentiment
Bullish
GB:0HOY Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.98%
12-Months-Change
Fundamentals
Return on Equity
11.71%
Trailing 12-Months
Asset Growth
11.99%
Trailing 12-Months
Company Description
Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
0HOY Company Deck
0HOY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, particularly in the Cardiovascular and Electrophysiology segments, with significant contributions from geographic expansion and product line success. However, challenges such as the discontinuation of the ACURATE valve and slow growth in certain regions were noted.View all GB:0HOY earnings summaries0HOY Revenue Breakdown
64.22% Cardiovascular
35.79% MedSurg
0HOY Stock 12 Month Forecast
Average Price Target
$125.09
▲(21.27% Upside)
Technical Analysis
Ownership Overview
0.16% Insiders
29.26%
Mutual Funds
0.87% Other Institutional Investors
48.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---